Evaluate the Safety, Tolerability, Pharmacokinetics of DR30206 in Patients With Advanced or Metastatic Solid Tumors
Condition: Solid Tumor · Sponsor: Zhejiang Doer Biologics Co., Ltd.
About this study
This study is to characterize the safety,tolerability, pharmacokinetics(PK),and preliminary anti-tumor activity of DR30206, in subjects with advanced or metastatic solid tumors
This description comes directly from the study's public registry record.
Talk to the study team
Senior Clinical Operations Director · +86 151 94 40 28 68 · yg@doerbio.com
Chief Operating Officer · +86 05 71 28 25 62 06 · yf@doerbio.com
Always discuss trial participation with your own doctor first.
Locations (1)
| Shanghai Pulmonary Hospital | Shanghai, Shanghai Municipality, China | Recruiting |
Follow this study
Save your interest here for when the public record changes — results posted, or the study's status changes. Email alerts for this study aren't switched on yet.
We keep this only about this public record, and never email you without alerts being switched on. Want it removed at any time? Email hello@eichor.com. Never medical advice. By subscribing you agree to our Terms of Use and Privacy Policy.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06132828